ABP
Price
$6.14
Change
-$0.00 (-0.00%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
16.43M
Intraday BUY SELL Signals
CLYM
Price
$1.83
Change
-$0.08 (-4.19%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
125.46M
109 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABP vs CLYM

Header iconABP vs CLYM Comparison
Open Charts ABP vs CLYMBanner chart's image
Abpro Holdings
Price$6.14
Change-$0.00 (-0.00%)
Volume$833
Capitalization16.43M
Climb Bio
Price$1.83
Change-$0.08 (-4.19%)
Volume$504
Capitalization125.46M
ABP vs CLYM Comparison Chart in %
ABP
Daily Signal:
Gain/Loss:
CLYM
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ABP vs. CLYM commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABP is a Hold and CLYM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (ABP: $6.15 vs. CLYM: $1.84)
Brand notoriety: ABP and CLYM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABP: 13% vs. CLYM: 34%
Market capitalization -- ABP: $16.43M vs. CLYM: $125.46M
ABP [@Biotechnology] is valued at $16.43M. CLYM’s [@Biotechnology] market capitalization is $125.46M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABP’s FA Score shows that 1 FA rating(s) are green whileCLYM’s FA Score has 1 green FA rating(s).

  • ABP’s FA Score: 1 green, 4 red.
  • CLYM’s FA Score: 1 green, 4 red.
According to our system of comparison, both ABP and CLYM are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABP’s TA Score shows that 4 TA indicator(s) are bullish while CLYM’s TA Score has 3 bullish TA indicator(s).

  • ABP’s TA Score: 4 bullish, 3 bearish.
  • CLYM’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ABP is a better buy in the short-term than CLYM.

Price Growth

ABP (@Biotechnology) experienced а +1.99% price change this week, while CLYM (@Biotechnology) price change was -4.17% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.19%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was +63.93%.

Reported Earning Dates

CLYM is expected to report earnings on Mar 09, 2026.

Industries' Descriptions

@Biotechnology (-2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLYM($125M) has a higher market cap than ABP($16.4M). CLYM YTD gains are higher at: 2.222 vs. ABP (-88.547). CLYM has higher annual earnings (EBITDA): -4.68M vs. ABP (-10.56M). CLYM has more cash in the bank: 84.7M vs. ABP (2.01M). CLYM has less debt than ABP: CLYM (639K) vs ABP (2.23M). ABP has higher revenues than CLYM: ABP (183K) vs CLYM (0).
ABPCLYMABP / CLYM
Capitalization16.4M125M13%
EBITDA-10.56M-4.68M226%
Gain YTD-88.5472.222-3,985%
P/E RatioN/AN/A-
Revenue183K0-
Total Cash2.01M84.7M2%
Total Debt2.23M639K348%
TECHNICAL ANALYSIS
Technical Analysis
ABPCLYM
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
13%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bullish Trend 2 days ago
53%
Bullish Trend 2 days ago
75%
MACD
ODDS (%)
Bullish Trend 2 days ago
43%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
40%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
35%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
56%
Bullish Trend 8 days ago
77%
Declines
ODDS (%)
Bearish Trend 6 days ago
76%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ABP
Daily Signal:
Gain/Loss:
CLYM
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DPRO7.150.49
+7.36%
Draganfly Inc
AD45.170.64
+1.44%
Array Digital Infrastructure Inc
VTS21.11-0.11
-0.52%
Vitesse Energy
NCRA1.09-0.02
-1.36%
Nocera
NOK6.03-0.61
-9.19%
Nokia Corp

ABP and

Correlation & Price change

A.I.dvisor tells us that ABP and NGNE have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ABP and NGNE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABP
1D Price
Change %
ABP100%
+0.16%
NGNE - ABP
31%
Poorly correlated
-1.64%
CLYM - ABP
27%
Poorly correlated
-3.66%
QSI - ABP
27%
Poorly correlated
+0.79%
ATYR - ABP
25%
Poorly correlated
-3.27%
HOWL - ABP
25%
Poorly correlated
+1.04%
More

CLYM and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLYM has been loosely correlated with KYTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CLYM jumps, then KYTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLYM
1D Price
Change %
CLYM100%
-3.66%
KYTX - CLYM
43%
Loosely correlated
+5.11%
PDSB - CLYM
41%
Loosely correlated
-4.93%
IPSC - CLYM
41%
Loosely correlated
+4.82%
RXRX - CLYM
40%
Loosely correlated
-3.12%
PRME - CLYM
39%
Loosely correlated
+4.65%
More